Patient-Derived Gastric Cancer Assembloids: Modeling Tumor–Stroma Complexity

Study Background and Research Question

Gastric cancer is among the five most common malignancies globally and remains the second leading cause of cancer-related mortality. Despite the advancement of therapies targeting HER2 and VEGFR2, the five-year survival rate for patients with advanced or metastatic disease remains below 10% (source: paper). This dismal prognosis is largely attributed to the immense heterogeneity of gastric tumors and the inadequacy of existing in vitro models, which often lack the physiological complexity of the tumor microenvironment. Conventional organoid systems, while useful, fail to capture the nuanced interactions between tumor epithelial cells and the diverse stromal compartments—particularly cancer-associated fibroblasts and other stromal subtypes implicated in drug resistance and disease progression. Given these limitations, the central research question addressed by Shapira-Netanelov et al. (2025) is: Can a patient-derived assembloid model, integrating matched tumor organoids and primary stromal cell subpopulations, better recapitulate the cellular heterogeneity and drug response landscape of gastric cancer compared to traditional models? (source: paper)

Key Innovation from the Reference Study

The primary innovation reported in this study is the development and validation of a gastric cancer assembloid model that incorporates both tumor organoids and stromal cell subpopulations derived from the same patient. Unlike previous three-dimensional cultures, this approach leverages autologous combinations of epithelial and stromal cells, maintaining patient-specific microenvironmental cues and cellular diversity (source: paper). The inclusion of tailored stromal cell types—such as mesenchymal stem cells, fibroblasts, and endothelial cells—enables the assembloid to more faithfully mimic the primary tumor’s gene expression patterns, cytokine milieu, and extracellular matrix dynamics. This, in turn, provides a superior platform for investigating drug responses, biomarker expression, and resistance mechanisms at a personalized level.

Methods and Experimental Design Insights

The authors employed a robust workflow for generating and characterizing the gastric cancer assembloids. After surgical resection, tumor specimens were enzymatically dissociated, and single-cell suspensions were cultured in specialized media formulated to support the expansion of tumor epithelial cells (for organoids), mesenchymal stem cells, fibroblasts, and endothelial cell populations. Each cell type was validated using immunofluorescence staining for lineage-specific markers. Crucially, the assembloid co-cultures were assembled by combining these matched, patient-derived subpopulations in an optimized medium that supports all cell types. Transcriptomic profiling via RNA sequencing was conducted to assess the expression of key biomarkers and pathways. Drug sensitivity was evaluated using cell viability assays following exposure to a panel of chemotherapeutic and targeted agents, enabling direct comparison between organoid monocultures and assembloid co-cultures (source: paper).

Protocol Parameters

• Organoid culture medium | proprietary/optimized (not disclosed) | for expansion of tumor epithelial cells | tailored to maintain viability and phenotype | paper
• Stromal cell media | cell type-specific (MSCs, fibroblasts, endothelial) | for isolation and expansion of stromal subsets | maintains lineage identity | paper
• Co-culture ratio (tumor:stroma) | variable, patient-specific | assembloid assembly | recapitulates in vivo heterogeneity | paper
• Immunofluorescence staining | marker panel (e.g., EpCAM, Vimentin, CD31) | biomarker validation | confirms cell type identity | paper
• RNA sequencing | bulk RNA-seq | transcriptomic profiling | assesses gene expression landscape | paper
• Drug response assay | cell viability (e.g., MTT, CellTiter-Glo) | sensitivity/resistance testing | determines treatment efficacy | paper

Core Findings and Why They Matter

The assembloid model successfully recapitulated the complex cellular architecture and microenvironmental signaling of primary gastric tumors. Key findings include:

• Assembloids showed robust co-expression of epithelial and stromal markers, confirming the preservation of cellular heterogeneity (source: paper).
• Transcriptomic analysis revealed that assembloids, compared to organoids alone, exhibited elevated expression of inflammatory cytokines, extracellular matrix remodeling factors, and genes associated with tumor progression.
• Drug sensitivity testing demonstrated pronounced patient- and drug-specific variability. Some therapeutic agents retained efficacy in both organoid and assembloid models, while others lost potency in the assembloid context, underscoring the critical modulatory role of the stromal compartment in mediating drug resistance.
• This model enables the study of cell–cell interactions and resistance mechanisms, which are not adequately captured by monoculture systems.

These findings are significant as they establish a physiologically relevant platform for high-fidelity preclinical drug screening and for dissecting the interplay between tumor and stroma in gastric cancer.

Comparison with Existing Internal Articles

Several recent articles have explored the integration of tumor-microenvironment complexity into preclinical modeling using fluoropyrimidine prodrugs such as Capecitabine. For example, "Capecitabine in Next-Generation Tumor Models" (internal article) and "Capecitabine: Precision Chemotherapy Design for Tumor-Selective Delivery" (internal article) both emphasize the value of integrating advanced assembloid platforms with apoptosis induction via Fas-dependent pathways and tumor-targeted drug delivery. The present study complements and extends these discussions by providing direct, patient-specific evidence that stromal subpopulations profoundly shape drug responsiveness—an insight hypothesized but not previously demonstrated in such controlled assembloid systems. While previous internal resources have highlighted Capecitabine as a model fluoropyrimidine prodrug for preclinical oncology research, the reference paper delivers a more granular understanding of microenvironment-driven resistance, supporting the rationale for incorporating patient-derived stromal diversity in future drug-testing workflows.

Limitations and Transferability

Despite its strengths, the assembloid approach has certain limitations. The co-culture ratios and media formulations require optimization for each patient, potentially limiting throughput and standardization. The model currently focuses on gastric cancer; transferability to other tumor types would require validation with tumor-specific stromal populations and adaptation of culture conditions (source: paper). Moreover, while transcriptomics and viability assays provide rich datasets, they may not fully capture long-term phenotypic adaptations or rare cellular events relevant for metastasis or recurrence.

Research Support Resources

To implement similar assembloid-based workflows and advance preclinical oncology research, investigators require reliable compounds for drug testing. Capecitabine (SKU A8647), also known as N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine, is a well-characterized fluoropyrimidine prodrug that is routinely used for apoptosis induction studies and tumor-targeted drug delivery in preclinical models. With validated purity and solubility profiles, Capecitabine from APExBIO is suitable for integration into assembloid systems to investigate chemotherapy selectivity, resistance mechanisms, and tumor–stroma interactions (source: product_spec). For best results, follow proper storage and usage protocols to maintain compound integrity and experimental reproducibility.